SCHEMBL2697367

SCHEMBL2697367

BrC(Br)=C=C(c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
CES1 P23141 3/20 0.38
CES2 O00748 2/20 0.38
TSHR P16473 2/20 0.38
DAO P14920 1/20 0.38
NAPRT Q6XQN6 1/20 0.38
TDP1 Q9NUW8 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
ATM Q13315 1/20 0.37
SRD5A2 P31213 1/20 0.37
PTPN1 P18031 1/20 0.36
GSK3B P49841 1/20 0.36
F2 P00734 2/20 0.35
CYP3A4 P08684 2/20 0.35
MAPT P10636 2/20 0.35
BLM P54132 2/20 0.35
CA2 P00918 2/20 0.35
CA4 P22748 2/20 0.35
F10 P00742 1/20 0.35
F12 P00748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181511 0.83 ALDH1A1 (0.53) ALDH1A1CES1CES2TSHRDAO
SCHEMBL8946209 0.74 ALDH1A1 (0.43) ALDH1A1CES1CES2TSHRDAO
SCHEMBL28883973 0.72 ALDH1A1 (0.42) ALDH1A1CES1CES2TSHRDAO
SCHEMBL7136968 0.71 CES1 (0.45) ALDH1A1CES1CES2TSHRDAO
SCHEMBL22151219 0.70 ALDH1A1 (0.40) ALDH1A1CES1CES2TSHRDAO
SCHEMBL5968341 0.67 CES1 (0.47) ALDH1A1CES1CES2TSHRDAO
SCHEMBL297692 0.67 CES1 (0.47) ALDH1A1CES1CES2TSHRDAO
SCHEMBL2523381 0.67 CES1 (0.47) ALDH1A1CES1CES2TSHRDAO
SCHEMBL10971959 0.67
SCHEMBL157488 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155382-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2014-06-05 US disclosed
EP-2651924-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2013-10-23 EP disclosed
WO-2012083164-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-06-21 WO disclosed
US-20120115918-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115918-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS ALDH1A1 2858/4885CES1 396/4885CES2 626/4885
US-20140155382-A1 ANTI-VIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS ALDH1A1 2858/4885CES1 396/4885CES2 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.